XML 28 R17.htm IDEA: XBRL DOCUMENT

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On April 28, 2017, the Company's first commercial product, TYMLOS (abaloparatide) injection was approved by the FDA for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. In connection with the FDA's approval on TYMLOS in April 2017, the Company is obligated to pay Ipsen a milestone of €8.0 million (approximately $8.7 million) under the License Agreement, which the Company will record as an intangible asset and amortize over the remaining term of the License Agreement or the expected product life-cycle for TYMLOS, whichever is shorter.